marked.bio

Company

Tango Therapeutics

2 active trials that select patients by a biomarker on marked.bio.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

zoldonrasib 1daraxonrasib 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

2 of 3 trials shown

  1. TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients

    Not yet recruiting Phase 1/2 Tango Therapeutics Started 2026Primary completion 2031-11 NCT07897734

    vopimetostatERAS-0015

    …ed, recurrent or metastatic NSCLC (no more than 2 prior lines of therapy) with documented KRAS mutation at G12X or G13X locally obtained via an analytically validated assay (Dose expansion only…

    KRAS G12CKRAS G12DPDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation

  2. Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

    Recruiting Phase 1/2 Tango Therapeutics Started 2025Primary completion 2027-06 NCT06922591

    TNG462zoldonrasibdaraxonrasibmFOLFIRINOXgemcitabinenab-paclitaxel

    Arms A and B only: Has a tumor with a RAS mutation

    KRAS G12CKRAS G12DPDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation